A study evaluating adherence to ALK inhibitors in patients with NSCLC reported that the proportion of patients with an MPR ≥ 80% ranged from 92 to 95% depending on the specific agent and whether the patients were naïve to ALK inhibitors (Ganti et al. 2022). Here, ALK is linked to non-small cell lung carcinoma.